{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A857", "status": "success", "status_code": 200, "timestamp_elapsed": 0.004381, "timestamp_received": "2026-09-25T00:13:56.193666+00:00Z", "timestamp_returned": "2026-09-25T00:13:56.198047+00:00Z", "trace_id": "0c93f2c4-d822-487c-aa5f-d8b9b3f1356b" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:zegfrovy:0:0", "type": "Statement", "description": "The U.S. Food and Drug Administration (FDA) granted approval to sunvozertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).", "contributions": [ { "id": "ctrb:vanallenlab:2025-09-03:0", "type": "Contribution", "description": "The US FDA approved sunvozertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.", "date": "2025-09-03", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2025-07-02:0", "type": "Contribution", "description": "Indication received accelerated approval.", "date": "2025-07-02", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:zegfrovy", "type": "Document", "documentType": "Regulatory approval", "name": "Zegfrovy (sunvozertinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Dizal (Jiangsu) Pharmaceutical Co., Ltd. Zegfrovy (sunvozertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219839s000lbl.pdf. Revised July 2025. Accessed September 3, 2025.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219839s000lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219839" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Dizal (Jiangsu) Pharmaceutical Co., Ltd.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Zegfrovy", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "sunvozertinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2025-07-02", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 219839, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-07-02", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:857", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:NSCLC", "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC" ] } }, "objectTherapeutic": { "id": "tx:ncit:C167205", "conceptType": "Therapy", "name": "Sunvozertinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2719226", "code": "2719226", "name": "sunvozertinib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2719226" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:37353667", "code": "37353667", "name": "sunvozertinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/37353667" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "EGFR inhibition", "HER2 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C167205", "code": "C167205", "name": "Sunvozertinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C167205" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:86", "present": true, "subject": { "id": "bmkr:86", "type": "CategoricalVariant", "name": "EGFR Exon 20 (Insertion)", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.wk0fEATa_DkPqxGhMRCFFPOXY9PMWpc1", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence within refseq:NP_005219.2, the protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to Exon 20.", "digest": "wk0fEATa_DkPqxGhMRCFFPOXY9PMWpc1", "sequenceReference": { "id": "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "type": "SequenceReference", "name": "NP_005219.2", "aliases": [ "ensembl:ENSP00000275493.2", "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "refseq:NP_005219.2" ], "description": "The protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to the Refseq protein accession NP_005219.2.", "moleculeType": "protein", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "residueAlphabet": "aa" }, "start": 761, "end": 823, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:3236", "conceptType": "Gene", "name": "EGFR", "primaryCoding": { "id": "coding:hgnc:3236", "code": "HGNC:3236", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000146648", "code": "ENSG00000146648", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000146648" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:1956", "code": "1956", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/1956" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005228.5", "code": "NM_005228.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "7" }, { "name": "start_position", "value": null }, { "name": "end_position", "value": null }, { "name": "reference_allele", "value": null }, { "name": "alternate_allele", "value": null }, { "name": "cdna_change", "value": null }, { "name": "protein_change", "value": null }, { "name": "variant_annotation", "value": "Insertion" }, { "name": "exon", "value": 20 }, { "name": "hgvsg", "value": null }, { "name": "hgvsc", "value": null } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:zegfrovy:0", "type": "Indication", "description": "ZEGFROVY is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).", "contributions": [ { "id": "ctrb:vanallenlab:2025-09-03:0", "type": "Contribution", "description": "The US FDA approved sunvozertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.", "date": "2025-09-03", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2025-07-02:0", "type": "Contribution", "description": "Indication received accelerated approval.", "date": "2025-07-02", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:zegfrovy", "type": "Document", "documentType": "Regulatory approval", "name": "Zegfrovy (sunvozertinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Dizal (Jiangsu) Pharmaceutical Co., Ltd. Zegfrovy (sunvozertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219839s000lbl.pdf. Revised July 2025. Accessed September 3, 2025.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219839s000lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219839" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Dizal (Jiangsu) Pharmaceutical Co., Ltd.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Zegfrovy", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "sunvozertinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2025-07-02", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 219839, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-07-02", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Accelerated", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }